Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,077 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Among authors: cheung l. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo.
Murray J, Valli E, Yu DMT, Truong AM, Gifford AJ, Eden GL, Gamble LD, Hanssen KM, Flemming CL, Tan A, Tivnan A, Allan S, Saletta F, Cheung L, Ruhle M, Schuetz JD, Henderson MJ, Byrne JA, Norris MD, Haber M, Fletcher JI. Murray J, et al. Among authors: cheung l. Eur J Cancer. 2017 Sep;83:132-141. doi: 10.1016/j.ejca.2017.06.024. Epub 2017 Jul 20. Eur J Cancer. 2017. PMID: 28735070 Free PMC article.
ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
Jung M, Gao J, Cheung L, Bongers A, Somers K, Clifton M, Ramsay EE, Russell AJ, Valli E, Gifford AJ, George J, Kennedy CJ, Wakefield MJ, Topp M, Ho GY; Australian Ovarian Cancer Study; Scott CL, Bowtell DD, deFazio A, Norris MD, Haber M, Henderson MJ. Jung M, et al. Among authors: cheung l. Int J Cancer. 2020 Oct 15;147(8):2225-2238. doi: 10.1002/ijc.33005. Epub 2020 May 8. Int J Cancer. 2020. PMID: 32277480 Free article.
Development of DNA probes for Candida albicans.
Cheung LL, Hudson JB. Cheung LL, et al. Diagn Microbiol Infect Dis. 1988 Jul;10(3):171-9. doi: 10.1016/0732-8893(88)90037-5. Diagn Microbiol Infect Dis. 1988. PMID: 3067959
Editorial: New advances on hypothalamus-pituitary stem cell biology.
Cheung L, Davis SW, Perez-Millan MI. Cheung L, et al. Front Endocrinol (Lausanne). 2024 Mar 11;15:1392076. doi: 10.3389/fendo.2024.1392076. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38529397 Free PMC article. No abstract available.
1,077 results